Utility of Multiple Increased Lung Cancer Tumor Markers in Treatment of Patients with Advanced Lung Adenocarcinoma
10.3779/j.issn.1009-3419.2017.10.05
- VernacularTitle:多项肺系统肿瘤标志物异常在晚期肺腺癌治疗中的作用
- Author:
PENG YAN
1
;
WANG YAN
;
HAO XUEZHI
;
LI JUNLING
;
LIU YUTAO
;
WANG HONGYU
Author Information
1. 中国医学科学院北京协和医学院肿瘤医院
- Keywords:
Lung adenocarcinoma;
Tumor marker;
Distant metastasis;
Maintenance therapy;
Relapse
- From:
Chinese Journal of Lung Cancer
2017;20(10):690-694
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Among frequently-used tumor markers in lung cancer, carcinoembry-onic antigen (CEA) and carbohydrate antigen 125 (CA125), cytokeratin 19 (CYFRA21-1) and squamous carcinoma antigen (SCC), neuron specific enolase (NSE) and pro-gastrin-releasing peptide (ProGRP) are respectively expressed highly in lung adenocarcinoma, lung squamous carcinoma and small cell lung cancer. By comparing patients with multiple increased tumor markers (group A) and patients with increase of CEA and/or CA125 (group B), this study aims to investigate the utility of multiple increased tumor markers in therapeutic evaluation and prediction of disease relapsing in patients with advanced lung adenocarcinoma. Methods Patients with stage IV lung adenocarcinoma who receiving the first line chemotherapy in Cancer Hospital, Chinese Academy of Medical Sciences were enrolled and ret-rospectively analyzed. Clinical characteristic, serum tumor markers before chemotherapy, efficacy evaluation, progres-sion-free survival (PFS) were analyzed. Results Except CEA and CA125, the highest ratio of increased tumor mark-ersin group A was CYFRA21-1 (93%), then was NSE (36%), SCC (13%) and ProGRP (12%). Patients with multiple increased tumor markers tend to have more distant metastasis(P<0.001)and shorter PFS(median PFS 5.3 months vs 7.3 months, P=0.016). The relapse risk was lower in patients who accepted maintenance therapy than those who didn' t accept maintenance therapy in both groups (P<0.001). Conclusion Patients with multiple increased tumor markers have high risk of relapse, and maintenance therapy can reduce relapse risk.
